HJ Lück

Advanced epithelial ovarian cancer: 1998 consensus statements

J. S. Berek, K. Bertelsen, Andreas du Bois et al. · Annals of Oncology · 1999 · 85 citations · Full text

Gynecological Surgery, Medicine, Gynecology +4

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer – a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

Andreas du Bois, HJ Lück, Jacobus Pfisterer et al. · Annals of Oncology · 2001 · 68 citations

Dose-finding Study, Medicine, Metronomic Therapy +8

First-Line Chemotherapy With Epirubicin, Paclitaxel, and Carboplatin for Advanced Ovarian Cancer: A Phase I/II Study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group

Andreas du Bois, HJ Lück, Thomas Bauknecht et al. · Journal of Clinical Oncology · 1999 · 42 citations

Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial

Peter Reichardt, Gϋnter von Minckwitz, HJ Lück et al. · European Journal of Cancer · 2001 · 38 citations

Metastatic Breast Cancer, New Standard, Breast Oncology +7

S2-4: GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis.

Volker Möbus, IJ Diel, Nadia Harbeck et al. · Cancer Research · 2011 · 22 citations

Breast Oncology, Superior Dfs, Gain Study +16